Omnicell (NASDAQ:OMCL) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened

Omnicell, Inc. (NASDAQ:OMCL)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $35.73 and traded as high as $51.14. Omnicell shares last traded at $50.30, with a volume of 270,997 shares traded.

Analyst Ratings Changes

OMCL has been the topic of a number of analyst reports. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research note on Wednesday, January 7th. Wells Fargo & Company upped their price objective on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. UBS Group set a $53.00 target price on Omnicell in a research report on Friday, January 16th. Benchmark boosted their target price on shares of Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $48.57.

Omnicell Stock Performance

The company has a quick ratio of 1.21, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average price of $44.06 and a 200 day moving average price of $35.73. The stock has a market cap of $2.26 billion, a PE ratio of 116.98, a price-to-earnings-growth ratio of 5.47 and a beta of 0.77.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares in the company, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.52% of the company’s stock.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC increased its holdings in shares of Omnicell by 6.6% in the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock valued at $196,000 after acquiring an additional 401 shares during the period. Thrivent Financial for Lutherans grew its stake in Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after purchasing an additional 424 shares during the last quarter. Martin & Co. Inc. TN raised its holdings in Omnicell by 0.4% in the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock worth $3,706,000 after purchasing an additional 443 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Omnicell by 0.3% during the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after buying an additional 448 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after buying an additional 458 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.